(Tromsø, 6 July 2017) Biotec Pharmacon ASA (OSE:Biotec) will host a Capital
Markets Day (CMD) with strategic update and outlook on Thursday, 17 August 2017
following the Q2 presentation.
Time: 08.30 - 11.30
Location: Hotel Continental, Stortingsgaten 24/26, Oslo
The presentation will among other include:
· Woulgan - driving sales in key markets and next generation products
· Animal Health - continue securing high volume sales
· Human Health - competitive priced high quality prdoduct
· Enzymes - taking ArcticZymes to the next level
· Cancer - opportunity with untapped potential
· Execution on corporate strategy
For practical reasons, investors, analysts and journalists coming to the event
are encouraged to register via email to ir@biotec.no by 11th August 2017.
The Q2 and the CMD presentations will be webcasted live and made available on
www.biotec.no and through NewsWeb on 17 August 2017. It will be possible to post
questions through the webcast console
For additional information and booking of one-to-one meetings following the CMD,
please contact:
CFO
Børge Sørvoll
+47 95 29 01 87
borge.sorvoll@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, a premium priced product in the
advanced wound care market. ArcticZymes develops, produces and markets enzymes
of marine origin used in molecular DNA technologies and diagnostics,
representing growth markets where rapid technological developments are creating
a strong demand for new and improved enzymes.